OpenScience.ink

1 week ago • Diabetes care

Comparing Semaglutide, Dulaglutide, and Liraglutide in Patients on Kidney DialysisTarget Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.

Article

1 week ago • JDR clinical and translational research

Mouth and Dental Side Effects of GLP-1 Receptor Agonist MedicationsOral Health-Related Adverse Events of GLP-1 Receptor Agonists.

📖 Top 20% JournalArticle

1 week ago • Drug discovery today

How matching drug targets, types, and forms explains treatments using hormone and nutrient sensors for type 2 diabetesIncretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target-modality-formulation matching explains.

Article

1 week ago • Kidney medicine

Risk of Diabetic Eye Disease in People with Moderate to Severe Kidney Disease and Type 2 Diabetes Starting SGLT2 Inhibitors Versus GLP-1 Receptor AgonistsDiabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes.

📖 Top 20% JournalArticle

1 week ago • Diabetes research and clinical practice

Thyroid monitoring during GLP-1 receptor agonist treatment and its possible link to thyroid cancer detectionThyroid surveillance practices in GLP-1 receptor agonist use and its potential influence on thyroid cancer detection: A scoping review.

🎖️ Top 10% JournalArticle

1 week ago • Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Use of Glucagon-like Peptide-1 Receptor Agonists and Risk of Lymphedema After Breast Cancer SurgeryGlucagon-like peptide-1 receptor agonist use and risk of postmastectomy lymphedema in breast cancer survivors: a multicenter real-world cohort study.

📖 Top 20% JournalMulticenter Study

1 week ago • Medicine

Effectiveness and safety of GLP-1 drugs in people with fatty liver disease linked to metabolism problems and liver inflammationEfficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.

📖 Top 50% JournalSystematic Review

1 week ago • Diabetes, obesity & metabolism

How well and how safely CagriSema works for Type 2 Diabetes at different doses compared to other treatmentsEfficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

Article

1 week ago • Obesity pillars

Orforglipron's safety and effectiveness in adults with mild overweight and fat-related health problemsEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.

📖 Top 20% JournalArticle

1 week ago • Clinical pharmacology and therapeutics

Use of Three Diabetes Medicines and New Low Sodium Levels in Patients with Type 2 DiabetesUse of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations.

🥉 Top 5% JournalArticle

1 week ago • Pharmacoepidemiology and drug safety

Link between Semaglutide and Panic Attacks: Comparing Reports Over Time to Check for Bias in Drug Safety DataSemaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.

Article

1 week ago • Aesthetic plastic surgery

Comparing Results of Tummy Tuck Surgery After Large Weight LossA Comparative Outcome Review of Abdominoplasty Following Massive Weight Loss.

📖 Top 20% JournalArticle

1 week ago • Nutrients

How Gut Bacteria and Inflammation May Affect Appetite and Eating Behavior in ObesityThe Microbiota-Gut-Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior.

🎖️ Top 10% JournalArticle

1 week ago • BMC pharmacology & toxicology

Reports of brain-related side effects from GLP-1 diabetes treatments based on global safety dataNeuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).

📖 Top 30% JournalArticle

1 week ago • Maturitas

Incretin-based treatments for women during menopause: Current overviewIncretin-based therapies in menopause: Current landscape.

📖 Top 20% JournalArticle

1 week ago • Cureus

Surgery Safety and Results Linked to GLP-1-Based TreatmentsPerioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review.

Article

1 week ago • Heart rhythm

Risk of Irregular Heartbeats Linked to Drugs That Activate Glucagon-Like Peptide-1 Receptors: A Comparative AnalysisGlucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.

🥉 Top 5% JournalArticle

1 week ago • Cureus

IcoSema's role in weight loss and blood sugar control: A review and analysisIcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis.

Article

1 week ago • Advances in therapy

Skeletal Muscle and Its Response to Heart, Kidney, and Metabolism Treatments in Vulnerable Patients: SGLT2 Inhibitors, Incretin-Based Drugs, and Challenges in Personalized CareSkeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.

📖 Top 20% JournalArticle

1 week ago • Journal of personalized medicine

Current Understanding and Future Outlook of Semaglutide in Irregular HeartbeatsSemaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives.

📖 Top 20% JournalArticle

1 week ago • Hand (New York, N.Y.)

Use of a Blood Sugar Drug Linked to More Nerve Pressure Problems After Weight Loss SurgeryGlucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Increased Peripheral Nerve Compression After Bariatric Surgery.

📖 Top 30% JournalArticle

1 week ago • Zhonghua yi xue za zhi

Effectiveness and safety of locally made semaglutide injections in type 2 diabetes patients not well controlled by metformin: a multicenter phase 3 trial[Efficacy and safety of domestic semaglutide injection in patients with type 2 diabetes mellitus inadequately controlled with metformin: a multicenter, randomized, controlled phase 3 equivalence clinical trial].

English Abstract

1 week ago • Diabetes, obesity & metabolism

Brain and mental health outcomes linked to diabetes drug use in Medicare patients with type 2 diabetes, varying by treatment type and obesityNeuropsychiatric Outcomes Associated With GLP-1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status.

Article

1 week ago • Cells

Tirzepatide reduces lung blood vessel changes in pulmonary arterial hypertension linked to the SIRT1/H4K12la/c-Jun pathwayTirzepatide Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension: Association with the SIRT1/H4K12la/c-Jun Axis.

🎖️ Top 10% JournalArticle

1 week ago • Cell metabolism

UBT251, a new drug targeting three hormone receptors, tested in adults with type 2 diabetes in a multi-site phase 2 trialUBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.

🥇 Top 1% JournalArticle

1 week ago • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Cell-Based Treatments Using Supportive Tissue Cells for Metabolic Problems Linked to Obesity: How They Work, Evidence for Use, and Future DirectionsMesenchymal stromal cell-based therapies for obesity-associated metabolic complications: Mechanistic insights, translational evidence, and future perspectives.

🎖️ Top 10% JournalArticle

1 week ago • Journal of cardiovascular development and disease

Changes in Heart Metabolism Related to Obesity and Fat Around the Heart in Atrial Fibrillation with New Diabetes Drugs and Catheter TreatmentCardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation.

📖 Top 30% JournalArticle

1 week ago • Diseases (Basel, Switzerland)

Common Medication Use and Remaining Heart and Metabolic Risks in People with Type 2 Diabetes in RomaniaReal-World Pharmacological Patterns and Residual Cardiometabolic Risk in Patients with Type 2 Diabetes in Romania.

📖 Top 20% JournalArticle

1 week ago • European journal of obstetrics, gynecology, and reproductive biology

How common and changing use of weight-loss drugs is before and during pregnancy in the US from 2018 to 2023Prevalence and temporal trends of exposure to anti-obesity medications during preconception and pregnancy in a nationwide US claims database, 2018-2023.

Article

1 week ago • Life sciences

Lack of GHSR gene and LEAP2 treatment increase liraglutide’s blood sugar lowering effects in male mice depending on their metabolic stateGenetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner.

Article

← prevpage 5 of 16next →

Latest GLP-1 Therapies Research Papers